Challenges in the discovery and development of new agents for the treatment of obesity
- PMID: 17377527
- DOI: 10.1038/sj.clpt.6100161
Challenges in the discovery and development of new agents for the treatment of obesity
Abstract
New pharmacologic agents are being sought to help manage the epidemic of obesity and its consequences. Understanding the challenges of the history of obesity drugs is wise before investing in new obesity agents. Expectations of patients, physicians, and drug company executives are not consistent with characteristics of current agents or most potential new ones. Owing to the complex biology underlying body weight regulation, combinations of agents may be necessary to improve weight loss efficacy.
Similar articles
-
Obesity pharmacotherapy from a regulatory perspective: overview and key challenges.Clin Pharmacol Ther. 2007 May;81(5):756-60. doi: 10.1038/sj.clpt.6100169. Epub 2007 Mar 28. Clin Pharmacol Ther. 2007. PMID: 17392723 Review.
-
The success of bariatric surgery as treatment of type 2 diabetes should be a call to revitalize anti-obesity drug discovery and development.Curr Opin Investig Drugs. 2008 Apr;9(4):355-6. Curr Opin Investig Drugs. 2008. PMID: 18393101 No abstract available.
-
[Drug therapy of obesity--from bitter experiences to future possibilities].Lakartidningen. 2000 Apr 5;97(14):1726-8. Lakartidningen. 2000. PMID: 10815399 Swedish. No abstract available.
-
New drug targets for the treatment of obesity.Clin Pharmacol Ther. 2011 Jul;90(1):40-51. doi: 10.1038/clpt.2011.82. Epub 2011 Jun 8. Clin Pharmacol Ther. 2011. PMID: 21654742 Review.
-
Pharmacologic therapy for obesity.J La State Med Soc. 2005 Jan;157 Spec No 1:S56-64. J La State Med Soc. 2005. PMID: 15751911 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical